When the National Institute of Allergy and Infectious Diseases (NIAID) developed an experimental West Nile virus vaccine, it struggled to find an industry partner to take the product through advanced development and to the marketplace, despite a great public health need, said the agency's director, Anthony Fauci.
Not even the successful Phase I trial of the investigational West Nile product, which showed good safety and immunogenicity, was...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
